Wall Street analysts expect that Dermira Inc (NASDAQ:DERM) will report sales of $13.31 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Dermira’s earnings, with the highest sales estimate coming in at $14.00 million and the lowest estimate coming in at $12.70 million. Dermira reported sales of $2.24 million in the same quarter last year, which suggests a positive year over year growth rate of 494.2%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 25th.

According to Zacks, analysts expect that Dermira will report full year sales of $93.89 million for the current year, with estimates ranging from $93.30 million to $94.50 million. For the next financial year, analysts expect that the business will post sales of $70.85 million, with estimates ranging from $65.76 million to $73.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Dermira.

Dermira (NASDAQ:DERM) last announced its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.34. The firm had revenue of $11.53 million for the quarter, compared to analysts’ expectations of $11.07 million. Dermira had a negative net margin of 256.08% and a negative return on equity of 583.07%.

A number of research firms recently weighed in on DERM. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Dermira in a research report on Friday, October 18th. Zacks Investment Research raised shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price objective on the stock in a research report on Wednesday, October 9th. BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 19th. Finally, Leerink Swann reduced their price objective on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Dermira currently has a consensus rating of “Buy” and a consensus price target of $17.12.

In other news, CEO Thomas G. Wiggans bought 23,419 shares of the stock in a transaction on Monday, August 19th. The stock was bought at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the completion of the purchase, the chief executive officer now directly owns 39,666 shares in the company, valued at $338,747.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Matthew K. Fust sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the sale, the director now owns 11,051 shares of the company’s stock, valued at $96,917.27. The disclosure for this sale can be found here. 12.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Trellus Management Company LLC boosted its holdings in shares of Dermira by 50.0% in the 3rd quarter. Trellus Management Company LLC now owns 90,000 shares of the biopharmaceutical company’s stock valued at $575,000 after buying an additional 30,000 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Dermira by 12.3% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 18,552 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 2,031 shares in the last quarter. California Public Employees Retirement System boosted its holdings in shares of Dermira by 70.3% in the 3rd quarter. California Public Employees Retirement System now owns 24,119 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 9,958 shares in the last quarter. BB&T Securities LLC boosted its holdings in shares of Dermira by 38.1% in the 3rd quarter. BB&T Securities LLC now owns 39,452 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 10,892 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Dermira by 2.9% in the 3rd quarter. Rhumbline Advisers now owns 56,909 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 1,629 shares in the last quarter. Institutional investors own 94.44% of the company’s stock.

Dermira stock opened at $8.09 on Thursday. The company has a debt-to-equity ratio of 25.08, a current ratio of 7.03 and a quick ratio of 6.63. Dermira has a 1-year low of $5.25 and a 1-year high of $15.48. The firm has a market capitalization of $438.62 million, a P/E ratio of -1.54 and a beta of 1.33. The company’s 50-day moving average is $6.66 and its 200 day moving average is $8.54.

About Dermira

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

Further Reading: Price to Earnings Ratio (PE) Basics

Get a free copy of the Zacks research report on Dermira (DERM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.